XML 89 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments - Change in consideration receivable (Details) - Discontinued Operations, Disposed of by Sale - Elusys Therapeutics
12 Months Ended
Dec. 31, 2023
USD ($)
Contingent consideration receivable, related party  
Change in fair value  
Sale of Elusys Therapeutics $ 268,000
Balance at the ending 268,000
Consideration earn-out receivable, related party  
Change in fair value  
Sale of Elusys Therapeutics 1,720,000
Balance at the ending $ 1,720,000